This morning, February 17, 2021, we learned in two separate press releases that the European Commission has placed two new orders for additional doses of vaccine from the American laboratories Pfizer and Moderna. We would therefore like to inform you about these new orders with detailed figures.
First of all, the European Commission has decided to order 200 million additional doses of Comirnaty contra la Covid-19 vaccine from Pfizer BioNTech. This agreement will therefore make it possible to increase the doses distributed to the 27 Member States of the European Union in the coming weeks and months.
This new agreement signed with the American laboratory is in addition to the 300 million doses already ordered until 2021 under the first agreement signed last year. These 200 million additional doses will thus be delivered in 2021, a large part of which (75 million doses) will be delivered in the second quarter.
It should also be noted that the European Commission still has the possibility of ordering an additional 100 million doses of vaccine. This option, once exercised, would bring the total number of doses to be delivered by Pfizer to the European Union member states to nearly 600 million in total.
After Pfizer, another US biotech company, Moderna, announced that it has received an additional order for 150 million doses of its vaccine. In a press release this morning, Moderna announced that the European Commission has just placed an order for 150 million additional doses of its covid-19 vaccine. These new doses are expected to be delivered in the third or fourth quarter of 2021.
With this new contract, the order commitment confirmed by Brussels to Moderna is increased to 310 million doses for delivery in 2021. Under the terms of this agreement, the European Commission also has the option to purchase an additional 150 million doses, this time for delivery in 2022.
It should also be noted here that the European Commission has granted a conditional marketing authorization for Moderna's vaccine on the basis of a recommendation from the European Medicines Agency to prevent Covid-19 in people aged 18 years and older.
These data will, of course, need to be closely monitored to determine whether these additional doses will be sufficient to meet the needs and objectives of the European Union vaccination campaign.these data will of course need to be closely monitored to determine whether these additional doses will be sufficient to meet the needs and objectives of the European Union vaccination campaign and whether these two groups will be able to deliver the full number of doses ordered in a timely manner, especially since AstraZeneca vaccine does not appear to be effective against Covid-19 variants.